Peringatan Keamanan

There have not been reports of adverse events of diet supplementation with ubidecarenone.A31417 The normal side effects reported in humans are related to the gastrointestinal tract.A31416

Ubidecarenone

DB09270

small molecule approved investigational nutraceutical

Deskripsi

Ubidecarenone, also called coenzyme Q10, is a 1,4-benzoquinone. From its name (Q10), the Q refers to the constitutive quinone group, and 10 is related to the number of isoprenyl subunits in its tail.A7874 It is a powerful antioxidant, a lipid-soluble and essential cofactor in mitochondrial oxidative phosphorylation.A31413 The ubidecarenone is the coenzyme destined for mitochondrial enzyme complexes involved in oxidative phosphorylation in the production of ATP. It is fundamental for cells that have a high metabolic demand.L1062 Ubidecarenone is sold as a dietary supplement and is not FDA approved as a drug - it is not meant to treat, cure or prevent any disease. FDA does not approve this dietary supplements before sold nor regulate the manufacturing process.L1063

Struktur Molekul 2D

Berat 863.3435
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The pharmacokinetic properties may vary between different brands but studies have reported a half-life of ubidecarenone of 21.7 h.[A31414]
Volume Distribusi Ubidecarenone is distributed to the various tissues of the body and it is able to enter the brain.[L1065] In preclinical studies with intravenous administration of ubidecarenone, it is reported a volume of distribution of 20.4 L/kg which reflects its ability to penetrate extensively into organs and tissues.[A31415] AS a general rule, tissues with high-energy requirements or metabolic activity tend to presents higher amounts of ubidecarenone, these organs can be heart, kidney, liver and muscle.[A31416]
Klirens (Clearance) In preclinical studies with intravenous administration of ubidecarenone, it is reported a total clearance of 1.18 ml h/kg which was indicative of a prolonged elimination.[A31415]

Absorpsi

Ubidecarenone is absorbed from the small intestine into the lymphatics and then it can enter the blood. The hydrophobicity and large molecular weight limit its absorption making it very poor and variable depending on the food intake and the number of lipids presented in the food. The absorption is lower in the presence of an empty stomach and greater in presence of high lipid food diet. The daily dosage of ubidecarenone presents the reach of maximal serum concentration by reaching a plateau after three weeks.L1065 The pharmacokinetic properties may vary between different brands but studies have reported an AUC of 11.51 mcg h/ml and a Cmax of 0.32 mcg/ml at a time of 7.9 h.A31414

Metabolisme

Studies indicate that there is no saturation process during the metabolism of ubidecarenone. It is metabolized in all tissues by the phosphorylation in the cells and transportation to the kidneys for further excretion by the urine.L1066 After exerting its action, ubidecarenone is reduced and forms hydroquinone which is capable of recycling and regenerates other antioxidants such as tocopherol and ascorbate. The later metabolism of hydroquinone generates the formation of Q acid I and Q acid II in free and conjugated forms.A31416

Rute Eliminasi

The main elimination route of ubidecarenone is through the bile. After its oral administration, over 60% of the dose is excreted in the feces in the form of unchanged ubidecarenone and a small fraction of the metabolites.L1065, A31416 In the urine, ubidecarenone is bound to saposin B protein and represents only 8.3% of the total administered dose.A31416

Interaksi Makanan

1 Data
  • 1. Take with or without food. Many different products contain ubidecarenone; refer to the product monograph for more specific instructions.

Interaksi Obat

234 Data
Insulin pork The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Insulin pork.
Troglitazone The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Troglitazone.
Metformin The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Metformin.
Acetohexamide The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Acetohexamide.
Phenformin The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Phenformin.
Gliquidone The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Gliquidone.
Mitiglinide The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Mitiglinide.
Glisoxepide The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Glisoxepide.
Glymidine The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Glymidine.
AICA ribonucleotide The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with AICA ribonucleotide.
Buformin The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Buformin.
Vildagliptin The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Vildagliptin.
Voglibose The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Voglibose.
NN344 The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with NN344.
AMG-222 The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with AMG-222.
Bisegliptin The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Bisegliptin.
Alogliptin The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Alogliptin.
Gosogliptin The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Gosogliptin.
Glibornuride The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Glibornuride.
Benfluorex The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Benfluorex.
Empagliflozin The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Empagliflozin.
Albiglutide The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Albiglutide.
Dulaglutide The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Dulaglutide.
Lobeglitazone The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Lobeglitazone.
Netoglitazone The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Netoglitazone.
Rivoglitazone The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Rivoglitazone.
Ciglitazone The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Ciglitazone.
Lixisenatide The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Lixisenatide.
Insulin beef The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Insulin beef.
Insulin degludec The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Insulin degludec.
Insulin peglispro The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Insulin peglispro.
Insulin tregopil The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Insulin tregopil.
Ipragliflozin The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Ipragliflozin.
Dutogliptin The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Dutogliptin.
Allicin The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Allicin.
Tofogliflozin The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Tofogliflozin.
2,4-thiazolidinedione The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with 2,4-thiazolidinedione.
Teneligliptin The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Teneligliptin.
Omarigliptin The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Omarigliptin.
Carmegliptin The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Carmegliptin.
Gemigliptin The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Gemigliptin.
Anagliptin The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Anagliptin.
Evogliptin The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Evogliptin.
Sotagliflozin The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Sotagliflozin.
Balaglitazone The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Balaglitazone.
Remogliflozin etabonate The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Remogliflozin etabonate.
Carbutamide The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Carbutamide.
Guar gum The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Guar gum.
Metahexamide The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Metahexamide.
Semaglutide The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Semaglutide.
Taspoglutide The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Taspoglutide.
Englitazone The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Englitazone.
Tirzepatide The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Tirzepatide.
Gastric inhibitory polypeptide The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Gastric inhibitory polypeptide.
Insulin human The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Insulin human.
Insulin lispro The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Insulin lispro.
Insulin glargine The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Insulin glargine.
Glimepiride The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Glimepiride.
Sulfisoxazole The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Sulfisoxazole.
Disopyramide The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Disopyramide.
Acarbose The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Acarbose.
Sulfadiazine The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Sulfadiazine.
Rosiglitazone The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Rosiglitazone.
Miglitol The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Miglitol.
Chlorpropamide The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Chlorpropamide.
Nateglinide The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Nateglinide.
Pentamidine The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Pentamidine.
Tolazamide The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Tolazamide.
Repaglinide The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Repaglinide.
Glipizide The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Glipizide.
Gliclazide The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Gliclazide.
Tolbutamide The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Tolbutamide.
Pioglitazone The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Pioglitazone.
Exenatide The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Exenatide.
Mecasermin The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Mecasermin.
Pramlintide The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Pramlintide.
Insulin aspart The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Insulin aspart.
Insulin detemir The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Insulin detemir.
Insulin glulisine The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Insulin glulisine.
Saxagliptin The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Saxagliptin.
Liraglutide The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Liraglutide.
Quinine The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Quinine.
Mifepristone The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Mifepristone.
Glyburide The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Glyburide.
Bromocriptine The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Bromocriptine.
Sitagliptin The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Sitagliptin.
Sunitinib The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Sunitinib.
Dapagliflozin The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Dapagliflozin.
Linagliptin The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Linagliptin.
Canagliflozin The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Canagliflozin.
Ertugliflozin The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Ertugliflozin.
Pegvisomant The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Ubidecarenone.
Pregabalin The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Ubidecarenone.
Gatifloxacin The risk or severity of hypoglycemia can be increased when Gatifloxacin is combined with Ubidecarenone.
Escitalopram The risk or severity of hypoglycemia can be increased when Escitalopram is combined with Ubidecarenone.
Dapoxetine The risk or severity of hypoglycemia can be increased when Dapoxetine is combined with Ubidecarenone.
Milnacipran The risk or severity of hypoglycemia can be increased when Milnacipran is combined with Ubidecarenone.
Pasireotide The risk or severity of hypoglycemia can be increased when Pasireotide is combined with Ubidecarenone.
Desvenlafaxine The risk or severity of hypoglycemia can be increased when Desvenlafaxine is combined with Ubidecarenone.
Lanreotide The risk or severity of hypoglycemia can be increased when Lanreotide is combined with Ubidecarenone.

Target Protein

NADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial NDUFV3
Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial SDHA

Referensi & Sumber

Artikel (PubMed)
  • PMID: 7599208
    Ernster L, Dallner G: Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta. 1995 May 24;1271(1):195-204.
  • PMID: 29190916
    Xue R, Yang J, Wu J, Meng Q, Hao J: Coenzyme Q10 inhibits the activation of pancreatic stellate cells through PI3K/AKT/mTOR signaling pathway. Oncotarget. 2017 Sep 23;8(54):92300-92311. doi: 10.18632/oncotarget.21247. eCollection 2017 Nov 3.
  • PMID: 19281730
    Kang EY, Choi JW, Gwak HS, Chun IK: Comparison of bioavailability of two ubidecarenone products in healthy Korean volunteers. Int J Clin Pharmacol Ther. 2009 Mar;47(3):207-14.
  • PMID: 19240848
    Kalenikova EI, Gorodetskaya EA, Medvedev OS: Pharmacokinetics of coenzyme q10. Bull Exp Biol Med. 2008 Sep;146(3):313-6.
  • PMID: 16551570
    Bhagavan HN, Chopra RK: Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic Res. 2006 May;40(5):445-53. doi: 10.1080/10715760600617843.
  • PMID: 12374491
    Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M: Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002 Oct;59(10):1541-50.

Contoh Produk & Brand

Produk: 152 • International brands: 0
Produk
  • Acti-ubiquinone 50 Cap 50mg
    Capsule • 50 mg / cap • Oral • Canada • OTC • Approved
  • Amladex
    Tablet • - • Oral • US
  • B.E.T. Complex
    Tablet • - • Oral • Canada • OTC • Approved
  • Bio Sun
    Stick • - • Cutaneous • US • OTC
  • Biogard Ubiquinone Cap 30mg
    Capsule • 30 mg • Oral • Canada • OTC • Approved
  • Biomed Co Q 10
    Capsule • 100 mg / cap • Oral • Canada • OTC • Approved
  • Biosculpt
    Solution • - • Oral • Canada • OTC • Approved
  • C.V. Formula
    Liquid • - • Oral • Canada • OTC • Approved
Menampilkan 8 dari 152 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul